An interventional study of Expectation optimization in Atrial Fibrillation, sponsored by Evangelical Hospital Düsseldorf. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Evangelical Hospital Düsseldorf · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.
Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 238th largest by planned enrollment of the 284 interventional ones that give a count, is one of 16 that started in 2022, is one of 166 with no phase, reaches primary completion later than 30 of the 87 other live ones, and was the 326th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
Ages 18–99
Marien Hospital Herne · Sites in Germany
Ages 18+
St. Josefs-Hospital Wiesbaden GmbH · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Bayer · Sites in Germany, United States, Belgium and 5 more countries
Ages 18–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 44 · Phase 4 51
First in 2000; this study’s year is marked. 16 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 200 across the 284 interventional studies, 515 across the 131 observational. Of the 289 that completed or were terminated, 92 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
214 of 417 have an industry lead sponsor. The 10 most frequent:
Evangelical Hospital Düsseldorf is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Evangelical Hospital Düsseldorf has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
28 of the studies in Atrial Fibrillation with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT05557526Evangelical Hospital DüsseldorfOptimizing Quality of Life by Improved Patient Expectation Following Atrial Fibrillation Catheter Ablation | 2026-12 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
Add all 28 to your calendar (.ics) → With an account.
Among the 417 studies in Atrial Fibrillation with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim is to investigate whether optimizing patients' expectations towards the interventional treatment of atrial fibrillation (catheter ablation) leads to a lower disease-related impairment of the patients compared to the control group in the first three months after ablation (the so-called blanking period).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation without additional intervention.
Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation and an additional verbal intervention to optimize the expectation of the patient towards the procedure.
Other: Expectation optimization
A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
Quality of life (questionaire)
Quality of life of life will be compared between groups and between different time points (before versus 3 months after ablation) with "the atrial fibrillation effect on quality-of-life (AFEQT) questionnaire". An overall AFEQT score ranges from 0 to 100. A score of 0 corresponds to complete disability (or responding "extremely" limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding "not at all" limited, difficult or bothersome to all questions answered). Therefore, a positive change in score corresponds to improvement in AF symptoms.
Time frame: 3 months
Recurrence of atrial arrhythmias
Electrocardiographic documentation of any atrial arrhythmia with a duration \>30 sec
Time frame: 3 months
Recurrence of atrial arrhythmias
Electrocardiographic documentation of any atrial arrhythmia with a duration \>30 sec
Time frame: 12 months
Autonomic function (heart rate variability measurement)
Autonomic function will be assessed by heart rate variability measurement (low frequency and high frequency domain, root mean square of successive differences) to compare patients between groups and time points (before versus 3 months after ablation)
Time frame: 3 months
Atrial volume [ml/m2]
Atrial volume measured via echocardiography will be compared between groups and time points (before versus 3 months after ablation)
Time frame: 3 months
Left ventricular ejection fraction [%]
Left ventricular ejection fraction measured via echocardiography will be compared between groups and between time points (before versus 3 months after ablation)
Time frame: 3 months
Inflammatory markers from blood samples
Inflammatory markers (including IFN-gamma, TNF-alpha TGF-beta, IL-1beta, IL-4, IL-6, IL-8, IL-10, IL-1, CRP, MPO, NGF, S100B, ANP, FABP4) in blood samples measured via enzyme-linked immunosorbent assays will be compared between groups and between time points (before versus 3 months after ablation)
Time frame: 3 months
Treatment expectations (questionaire)
Treatment expectations will be measured using the GEEE (Generic rating scale for previous treatment experiences, treatment expectations, and treatment effects) questionaire by Rief et al. and compared between groups and between time points (before versus 3 months after ablation / before versus 12 months after ablation). The subscale Generic rating scale for treatment expectations consists of three items that assess expectations towards treatment on a numeric rating scale with eleven response options (0-10); total scores of all three subscales combined range from 0-30 with higher scores indicating higher treatment expectations.
Time frame: 3 months, 12 months
Physical Activity (questionaire)
Physical activity will be measured will be compared between groups and time points (before versus 3 months after ablation) using the short version of the International Physical Activity Questionnaire (IPAQ - short). The short version of the IPAQ is a 7-item questionnaire that assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives. Open-ended questions surrounding individuals' last 7-day recall of physical activity are considered to estimate total physical activity min/week and time spent sitting. Interpretation: Three levels (categories) of physical activity are proposed: low, moderate and high.
Time frame: 3 months, 12 months
General quality of life (questionaire)
General quality of life of life will be compared between groups and between different time points (before versus 3 months after ablation) with "F-36 questionaire. SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: 3 months, 12 months
Hospital Anxiety and Depression Scale HADS (questionaire)
Hospital anxiety and depression will becompared between groups and time points (before versus 3 months after ablation) using the Hospital Anxiety and Depression Scale (HADS). It consists of 14 items rated zero to three on Likert scales, allowing computation of sub-scores for depression and anxiety symptoms. Subscores as well as total sum score will be applied.
Time frame: 3 months, 12 months
Cardiac Anxiety Questionnaire CAQ (questionaire)
Cardiac anxiety will becompared between groups and time points (before versus 3 months after ablation) using the established Cardiac Anxiety Questionnaire CAQ to determine cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 68 for the German version, with a greater score indicating elevated cardiac anxiety.
Time frame: 3 months, 12 months
Plan to share: No
Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 54 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evangelical Hospital Düsseldorf